The incidence of PD at 3 years in the patients receiving a sulfonylurea was 0.49%, whereas that in those receiving a DPP-4 inhibitor was 0.49%, 0.52%, and 0.61% for patients with a cDDD of <75, 75–150, and >150, respectively. Here, DPP4 is linked to Parkinson disease.